EC Agrees to Phase in New IV Diagnostic Regulation, Starting in May

Companies that sell new diagnostics products in Europe got a much-needed dose of good news when the European Union (EU) announced that it has officially accepted a proposal to delay dramatic regulatory changes that most stakeholders just weren’t ready for. Bottom line: The EU In Vitro Diagnostic Regulation (IVDR) will still take effect on May 26, 2022 as scheduled, but it will be rolled out gradually in stages rather than in one fell swoop as originally planned.

EC Regulation of In Vitro Diagnostics

The European Commission (EC) and the European Parliament adopted the ((EU) 2017/746) legislative framework for regulation of in vitro medical devices, such as HIV, pregnancy, and SARS-CoV-2 tests in April 2017. That framework consists of two parts:

1. The new medical devices regulation (MDR); and
2. The IVDR.

The MDR was originally scheduled to take effect for two years, starting in May 2020, before being replaced by the IVDR in May 2022. Disruption from the global COVID-19 pandemic forced the postponement of the MDR; but the EC stubbornly stuck with the May 2022 deadline for the IVDR.

Impact on Laboratories and Device Companies

To comply with the regulation, labs, what are called “authorized representatives,” and other stakeholders must carry out major operational tasks such as revising documentation about their products, recruiting new staff, and updating internal procedures. Expecting all of this to be accomplished by May 26, 2022 was completely unrealistic, even in normal times. The other major bottleneck was the limited number and capacity of what are called notified bodies (NBs) responsible for certifying all of the diagnostics that need to be assessed for the first time before the IVDR can go into effect. The IVDR will bring around 80 percent of in vitro diagnostic medical devices under the control of NBs, as opposed to just the eight percent covered by current regulation. With the deadline less than a year away, only six entities were able to achieve certification. Even the EC acknowledged that lack of certification of NBs so close to the implementation date represents a “grave crisis.”

The New IVDR Rollout Plan

On October 12, 2021, the EC finally accepted reality and proposed a new rollout plan. After doubling down on May 26, 2022, the EC agreed to roll out the IVDR progressively. While leaving the substantive requirements intact, the new plan provides for longer transition periods, i.e., grace periods in which current certification will remain acceptable, for different types of devices, depending on the risks they pose:

• Certificates for lower-risk Class B and sterile Class A devices will remain valid until May 26, 2027;
• Certificates for medium-risk Class C devices, which covers most molecular tests, including genetic tests, companion diagnostics, infectious disease tests, and assays for stratifying cancer patients, will remain valid until May 26, 2026; and
• Certificates for higher-risk Class D devices, such as HIV or hepatitis tests, will remain valid until May 26, 2025

The new compliance deadline for in-house devices is May 26, 2024. Exception: The provision requiring labs to justify their use of an in-house device instead of a commercial, compliant test, has been pushed back until May 26, 2028.

Caveat: May 2022 Deadline Still Applies to CE Devices

It’s important to note that the new rollout plan doesn’t delay the implementation deadline for CE-marked devices. Impact: All tests that don’t currently have CE-IVD certificates will require clearance by an NB under the new rules after May 26, 2022.